Abstract
The effect on the IGF system of 60 mg and 600 mg daily of raloxifene administered for 2 weeks prior to surgery was investigated in 37 postmenopausal women with breast cancer. Raloxifene significantly decreased insulin-like growth factor (IGF-I) as compared to placebo (P < 0.05) with no dose–response relationship. No significant change was observed in IGFBP-3, while the IGF-I/IGFBP-3 molar ratio was decreased by treatment, with a statistically significant effect only for the higher dose. Given that high plasma levels of IGF-I have been suggested as a risk factor for breast cancer, these findings provide further support for the potential activity of raloxifene in breast cancer prevention. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Baserga R (1995) The insulin-like growth factor-I receptor: a key to tumor growth?. Cancer Res 55: 249–252
Boonen S, Mohan S, Dequeker J, Aerssens J, Vanderschueren D, Verbeke G, Broos P, Bouillon R and Baylink DJ (1999) Down-regulation of the serum stimulatory components of the insulin-like growth factor (IGF) system (IGF-I, IGF-II, IGF binding protein [BP]-3, and IGFBP-5) in age-related (type II) femoral neck osteoporosis. J Bone Miner Res 14: 2150–2158
Brown PH and Lippman SM (2000) Chemoprevention of breast cancer. Breast Cancer Res Treat 62: 1–17
Burroughs KD, Dunn SE, Barrett JC and Taylor JA (1999) Insulin-like growth factor-I: a key regulator of human cancer risk (Editorial). J Natl Cancer Inst 91: 579–581
Buzdar AU, Marcus C, Holmes F, Hug V and Hortobagyi G (1988) Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology 45: 344–345
Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Scmitt H, Muchmore DB and Jordan VC (2001) Continued breast cancer risk reduction in postmenopausal women treated with raloxifene. 4-year results from the MORE trial. Breast Cancer Res Treat 65: 125–134
Collins D, Woods A, Herd R, Blake G, Fogelman I, Wheeler M and Swaminathan R (1998) Insulin-like growth factor-I and bone mineral density. Bone 23: 13–16
Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A and Jordan VC (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 281: 2189–2197
Cummings S (2000) The paradox of small changes in bone density vs large reduction in fracture risk. NIH Workshop on SERMs, National Cancer Institute, (26–28 April, 2000). 126–127
Daughaday WH, Mariz IK and Blethen SL (1980) Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: a comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol – extracted serum. J Clin Endocrinol Metab 51: 781–788
Decensi A, Bonanni B, Guerrieri-Gonzaga A, Gandini S, Robertson C, Johansson H, Travaglini R, Sandri MT, Tessadrelli A, Farante G, Salinaro F, Bettega D, Barreca A, Boyle P, Costa A and Veronesi U (1998) Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst 90: 1461–1467
Dowsett M, Bundred NJ, Decensi A, Sainsbury RC, Lu Y, Hills M, Cohen FJ, Veronesi P, O’Brien MER, Scott T and Muchmore DB (2001) Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. Cancer Epidemiol Biomarkers Prev 10: 361–366
Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P and Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 282: 637–645
Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L Wolmark N and other NSABP investigators (1998) Tamoxifen for prevention of breast cancer: report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371–1388
Garnero P, Sornay-Rendu E and Delmas PD (1999) Low serum IGF-I and occurrence of osteoporotic fractures in postmenopausal women. Lancet 355: 898–899
Goldstein H (1995) Multivariate statistical models. Halsted Press: New York
Gradishar W, Glusman J, Lu Y, Vogel C, Cohen FJ and Sledge GW Jr. (2000) Effects of high dose raloxifene in selected patients with advanced breast carcinoma. Cancer 88: 2047–2053
Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Spelzer FE and Pollak M (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351: 1393–1396
Helle SI, Anker GB, Tally M, Hall K and Lonning PE (1996) Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, Pro-IGF-IIE, insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-3 in breast cancer patients. J Steroid Biochem Mol Biol 57: 167–171
Kelloff GJ, Boone CW, Crowell JA, Steele VE, Lubet R and Doody LA (1994) Surrogate endpoint biomarkers for phase II cancer chemoprevention trials. J Cell Biochem S9: 1–9
Lonning PE, Hall K, Aakvaag A and Kien EA (1992) Influence of tamoxifen on plasma levels of insulin-like growth factor-I and insulin-like growth factor binding protein-1 in breast cancer patients. Cancer Res 52: 4719–4723
Ng ST, Zhou J, Adesanya O, Wang J, LeRoith D and Bondy CA (1997) Growth hormone treatment induces mammary gland hyperplasia in aging primates. Nat Med 3: 1141–1144
Pollak MN (1998) Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res Treat 47: 209–217
Pollak M (2000) Insulin-like growth factor physiology and cancer risk. Eur J Cancer 36: 1224–1228
Radmacher MD and Simon R (2000) Estimation of tamoxifen’s efficacy for preventing the formation and growth of breast tumors. J Natl Cancer Inst 92: 48–53
Toniolo P, Bruning PF, Akhmedkhanov A, Bonfrer JMG, Koenig KL, Lukanova A, Shore RE and Zeleniuch-Jacquotte A (2000) Serum insulin-like growth factor-I and breast cancer. Int J Cancer 88: 828–832
Torrisi R, Pensa F, Orengo MA, Catsafados E, Ponzani P, Boccardo F, Costa A and Decensi A (1993) The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I in breast cancer patients. Cancer Res 53: 4769–4771
Vadgama JV, Wu Y, Datta G, Khan H and Chillar R (1999) Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer and predict the risk of recurrence and the probability of survival in African–American and Hispanic women. Oncology 57: 330–340
Veronesi U, De Palo G, Marubini E, Costa A, Formelli F, Mariani L, Decensi A, Camerini T, Rosselli Del Turco M, Di Mauro MG, Muraca MG, Del Vecchio M, Pinto C, D’Aiuto G, Boni C, Campa T, Magni A, Miceli R, Perloff M, Malone WF and Sporn MB (1999) Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 91: 1847–1856
Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B and LeRoith D (1999) Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 96: 7324–7329
Yu H and Rohan T (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92: 1472–1489
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Torrisi, R., Baglietto, L., Johansson, H. et al. Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer. Br J Cancer 85, 1838–1841 (2001). https://doi.org/10.1054/bjoc.2001.2191
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2001.2191
Keywords
This article is cited by
-
Estrogens and selective estrogen receptor modulators in acromegaly
Endocrine (2016)
-
Administration of omega-3 fatty acids and Raloxifene to women at high risk of breast cancer: interim feasibility and biomarkers analysis from a clinical trial
European Journal of Clinical Nutrition (2012)
-
The effect of strontium ranelate on serum insulin like growth factor-1 and leptin levels in osteoporotic post-menopausal women: a prospective study
Archives of Gynecology and Obstetrics (2008)
-
Evaluation of insulin-like growth factor-I in postmenopausal women with breast cancer treated with raloxifene
International Seminars in Surgical Oncology (2007)
-
Is there an estrogenic component in the metabolic syndrome?
Genes & Nutrition (2006)
